Loading…

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia

We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactio...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2018-05, Vol.103 (5), p.888-898
Main Authors: Schroeder, Thies, Piantadosi, Claude A., Natoli, Michael J., Autmizguine, Julie, Cohen‐Wolkowieczs, Michael, Hamilton, Karyn L., Bell, Christopher, Klawitter, Jelena, Christians, Uwe, Irwin, David C., Noveck, Robert J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03
cites cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03
container_end_page 898
container_issue 5
container_start_page 888
container_title Clinical pharmacology and therapeutics
container_volume 103
creator Schroeder, Thies
Piantadosi, Claude A.
Natoli, Michael J.
Autmizguine, Julie
Cohen‐Wolkowieczs, Michael
Hamilton, Karyn L.
Bell, Christopher
Klawitter, Jelena
Christians, Uwe
Irwin, David C.
Noveck, Robert J.
description We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.
doi_str_mv 10.1002/cpt.860
format article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5947522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</originalsourceid><addsrcrecordid>eNp1kN1LwzAUxYMobk7xP5C--SCd-Wja5EUYZTph4MD5HNI02SJtU9L60f_ezKnog0-Xwz33dw8HgHMEpwhCfK3afspSeADGiBIcp5TQQzCGEPKYY5KOwEnXPQeZcMaOwQgzRjOUZGOwfpRG90MkmzKa-43b6MaqaOVdq31vdRc5E-WuLmyjy2hW28a126Gqgvw8mdWFt51uetlEtokWQ-verTwFR0ZWnT77mhPwdDtf54t4-XB3n8-WsUoyCmNJE2NQyiGB1ASBGCkQpMgQQnGSpqRITYZ5RhPFeEkSUyhVQpgVnDMFJSQTcLPnti9FrUsVcnhZidbbWvpBOGnF301jt2LjXgXlIQDGAXC5Byjvus5r83OLoNgVK0KxIhQbnBe_X_34vpsMhqu94c1WeviPI_LVeof7AKbbgnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</creator><creatorcontrib>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</creatorcontrib><description>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P &lt; 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% &gt;placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.860</identifier><identifier>PMID: 28857147</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>Adenosine - metabolism ; Adolescent ; Adult ; Altitude ; Aminophylline - adverse effects ; Aminophylline - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination - adverse effects ; Endothelins - drug effects ; Endothelins - metabolism ; Exercise - physiology ; Female ; Humans ; Hypoxia - drug therapy ; Hypoxia - metabolism ; Male ; Middle Aged ; Phenylpropionates - adverse effects ; Phenylpropionates - therapeutic use ; Pyridazines - adverse effects ; Pyridazines - therapeutic use ; Signal Transduction - drug effects ; Young Adult</subject><ispartof>Clinical pharmacology and therapeutics, 2018-05, Vol.103 (5), p.888-898</ispartof><rights>2017 The Authors Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</rights><rights>2017 The Authors Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</citedby><cites>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</cites><orcidid>0000-0002-6320-8824 ; 0000-0003-1893-6141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28857147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schroeder, Thies</creatorcontrib><creatorcontrib>Piantadosi, Claude A.</creatorcontrib><creatorcontrib>Natoli, Michael J.</creatorcontrib><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Cohen‐Wolkowieczs, Michael</creatorcontrib><creatorcontrib>Hamilton, Karyn L.</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><creatorcontrib>Klawitter, Jelena</creatorcontrib><creatorcontrib>Christians, Uwe</creatorcontrib><creatorcontrib>Irwin, David C.</creatorcontrib><creatorcontrib>Noveck, Robert J.</creatorcontrib><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P &lt; 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% &gt;placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</description><subject>Adenosine - metabolism</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Altitude</subject><subject>Aminophylline - adverse effects</subject><subject>Aminophylline - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Endothelins - drug effects</subject><subject>Endothelins - metabolism</subject><subject>Exercise - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoxia - drug therapy</subject><subject>Hypoxia - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenylpropionates - adverse effects</subject><subject>Phenylpropionates - therapeutic use</subject><subject>Pyridazines - adverse effects</subject><subject>Pyridazines - therapeutic use</subject><subject>Signal Transduction - drug effects</subject><subject>Young Adult</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kN1LwzAUxYMobk7xP5C--SCd-Wja5EUYZTph4MD5HNI02SJtU9L60f_ezKnog0-Xwz33dw8HgHMEpwhCfK3afspSeADGiBIcp5TQQzCGEPKYY5KOwEnXPQeZcMaOwQgzRjOUZGOwfpRG90MkmzKa-43b6MaqaOVdq31vdRc5E-WuLmyjy2hW28a126Gqgvw8mdWFt51uetlEtokWQ-verTwFR0ZWnT77mhPwdDtf54t4-XB3n8-WsUoyCmNJE2NQyiGB1ASBGCkQpMgQQnGSpqRITYZ5RhPFeEkSUyhVQpgVnDMFJSQTcLPnti9FrUsVcnhZidbbWvpBOGnF301jt2LjXgXlIQDGAXC5Byjvus5r83OLoNgVK0KxIhQbnBe_X_34vpsMhqu94c1WeviPI_LVeof7AKbbgnA</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Schroeder, Thies</creator><creator>Piantadosi, Claude A.</creator><creator>Natoli, Michael J.</creator><creator>Autmizguine, Julie</creator><creator>Cohen‐Wolkowieczs, Michael</creator><creator>Hamilton, Karyn L.</creator><creator>Bell, Christopher</creator><creator>Klawitter, Jelena</creator><creator>Christians, Uwe</creator><creator>Irwin, David C.</creator><creator>Noveck, Robert J.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6320-8824</orcidid><orcidid>https://orcid.org/0000-0003-1893-6141</orcidid></search><sort><creationdate>201805</creationdate><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><author>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenosine - metabolism</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Altitude</topic><topic>Aminophylline - adverse effects</topic><topic>Aminophylline - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Endothelins - drug effects</topic><topic>Endothelins - metabolism</topic><topic>Exercise - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoxia - drug therapy</topic><topic>Hypoxia - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenylpropionates - adverse effects</topic><topic>Phenylpropionates - therapeutic use</topic><topic>Pyridazines - adverse effects</topic><topic>Pyridazines - therapeutic use</topic><topic>Signal Transduction - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schroeder, Thies</creatorcontrib><creatorcontrib>Piantadosi, Claude A.</creatorcontrib><creatorcontrib>Natoli, Michael J.</creatorcontrib><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Cohen‐Wolkowieczs, Michael</creatorcontrib><creatorcontrib>Hamilton, Karyn L.</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><creatorcontrib>Klawitter, Jelena</creatorcontrib><creatorcontrib>Christians, Uwe</creatorcontrib><creatorcontrib>Irwin, David C.</creatorcontrib><creatorcontrib>Noveck, Robert J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schroeder, Thies</au><au>Piantadosi, Claude A.</au><au>Natoli, Michael J.</au><au>Autmizguine, Julie</au><au>Cohen‐Wolkowieczs, Michael</au><au>Hamilton, Karyn L.</au><au>Bell, Christopher</au><au>Klawitter, Jelena</au><au>Christians, Uwe</au><au>Irwin, David C.</au><au>Noveck, Robert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2018-05</date><risdate>2018</risdate><volume>103</volume><issue>5</issue><spage>888</spage><epage>898</epage><pages>888-898</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P &lt; 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% &gt;placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>28857147</pmid><doi>10.1002/cpt.860</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6320-8824</orcidid><orcidid>https://orcid.org/0000-0003-1893-6141</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2018-05, Vol.103 (5), p.888-898
issn 0009-9236
1532-6535
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5947522
source Wiley-Blackwell Read & Publish Collection
subjects Adenosine - metabolism
Adolescent
Adult
Altitude
Aminophylline - adverse effects
Aminophylline - therapeutic use
Double-Blind Method
Drug Therapy, Combination - adverse effects
Endothelins - drug effects
Endothelins - metabolism
Exercise - physiology
Female
Humans
Hypoxia - drug therapy
Hypoxia - metabolism
Male
Middle Aged
Phenylpropionates - adverse effects
Phenylpropionates - therapeutic use
Pyridazines - adverse effects
Pyridazines - therapeutic use
Signal Transduction - drug effects
Young Adult
title Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A17%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Ergogenic%20Properties%20of%20Combined%20Aminophylline%20and%20Ambrisentan%20in%20Hypoxia&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Schroeder,%20Thies&rft.date=2018-05&rft.volume=103&rft.issue=5&rft.spage=888&rft.epage=898&rft.pages=888-898&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.860&rft_dat=%3Cwiley_pubme%3ECPT860%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28857147&rfr_iscdi=true